Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG‐IBD LIVE study

BACKGROUND: Vedolizumab registration trials were the first to include elderly patients with moderate‐to‐severe ulcerative colitis (UC) or Crohn’s disease (CD), but few real‐life data have been reported in this population. AIMS: We investigated the effectiveness and safety of vedolizumab in matched c...

Descripción completa

Detalles Bibliográficos
Autores principales: Pugliese, Daniela, Privitera, Giuseppe, Crispino, Federica, Mezzina, Nicolò, Castiglione, Fabiana, Fiorino, Gionata, Laterza, Lucrezia, Viola, Anna, Bertani, Lorenzo, Caprioli, Flavio, Cappello, Maria, Barberio, Brigida, Ricci, Chiara, Balestrieri, Paola, Daperno, Marco, Pluchino, Dario, Rizzello, Fernando, Scribano, Maria Lia, Sablich, Renato, Pastorelli, Luca, Manguso, Francesco, Variola, Angela, Di Sario, Antonio, Grossi, Laurino, Armuzzi, Alessandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Age‐related Efficacy and Safety of Vedolizumab
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9324100/
https://www.ncbi.nlm.nih.gov/pubmed/35876062
http://dx.doi.org/10.1111/apt.16923

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9324100/
https://www.ncbi.nlm.nih.gov/pubmed/35876062
http://dx.doi.org/10.1111/apt.16923

Ejemplares similares